Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PROPAFENONE HCL

All products: general benefit

Other products in the same Health Canada class (C01B, C01BC) — coverage varies; not interchangeable

  • Flecainide (Tambocor): general benefit, Not a benefit
  • Amiodarone (Cordarone): general benefit, Not a benefit
  • Disopyramide (Norpace): general benefit, Not a benefit, Listing status unconfirmed
  • Mexiletine (Mexitil): general benefit, Not a benefit

Rythmol · DIN 00603716 · 300mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Rythmol (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Rythmol · DIN 00603716 Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01 Health Canada: Marketed since 2016-06-17 · brand RYTHMOL · ATC C01BC03 PROPAFENONE · form Tablet · route Oral · ingredients PROPAFENONE HYDROCHLORIDE 300 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $1.1116 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8465 · Verify on the e-Formulary ↗ (DIN 00603716)

Source record
DIN 00603716: Rythmol Raw flags: chronicUseMed=Y, sec3=Y Item: 240400092; group id 289; item number 0621; lccId None; manufacturer id ABB Source form: Tab; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $2.6915; ministry $1.1116 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00603716 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8465
Interchangeable products
Apo-Propafenone · DIN 02243325 · $1.1116 Mylan-Propafenone · DIN 02457164 · $1.1116
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered

Matched class: 24:04 Cardiac Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE, VERAPAMIL HCL 24:00 CARDIOVASCULAR DRUGS

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:04 Cardiac Drugs

FLECAINIDE ACETATE

· 14 products · Listed, not a benefit (2), General benefit (12) · strengths: 50mg, 100mg · Tab

AMIODARONE HCL

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab

DISOPYRAMIDE

· 3 products · Listed, not a benefit (1), General benefit (1), Temporary benefit (1) · strengths: 100mg · Cap

MEXILETINE HCL

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 100mg, 200mg · Cap

ACEBUTOLOL HCL

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab

AMLODIPINE

· 56 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

DIGOXIN

· 7 products · General benefit · strengths: 0.05mg/mL, 0.0625mg, 0.125mg · O/L, Tab

DILTIAZEM HCL

· 93 products · General benefit (91), Listed, not a benefit (2) · strengths: 120mg, 180mg, 240mg, 300mg, 360mg, 30mg, 60mg · ER Tab, LA Cap, SR Cap, Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:04 and 9 more
Full class listing Related classes: 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: documented life-threatening ventricular arrhythmias, documented symptomatic ventricular arrhythmias
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. MEXILETINE HCL · Listed, not a benefit (2), General benefit (4) 1 INDICATIONS TEVA-MEXILETINE (mexiletine hydrochloride) is indicated for: • the treatment of documented life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia. PM: https://pdf.hres.ca/dpd_pm/00073596.PDF; date November 27, 2023; DIN 02230359; fetched 2026-09-10 Product monograph • the treatment of patients with documented symptomatic ventricular arrhythmias when the symptoms are of sufficient severity to require treatment. Because of the proarrhythmic effects of mexiletine, its use should be reserved for patients in whom, in the opinion of the physician, the benefit of treatment clearly outweighs the risks. PM: https://pdf.hres.ca/dpd_pm/00073596.PDF; date November 27, 2023; DIN 02230359; fetched 2026-09-10 Product monograph SOTALOL HCL · Listed, not a benefit (2), General benefit (8) APO-SOTALOL may also be used for the treatment of patients with documented symptomatic ventricular arrhythmias when the symptoms are of sufficient severity to require treatment. PM: https://pdf.hres.ca/dpd_pm/00066796.PDF; date July 22, 2022; DIN 02167794; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS RYTHMOL® (propafenone hydrochloride) is indicated for:  the treatment of documented life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia prevention. RYTHMOL® may also be used for the treatment of patients with documented symptomatic ventricular arrhythmias when the symptoms are of sufficient severity to require treatment. Because of the proarrhythmic effects of RYTHMOL®, its use should be reserved for patients in whom, in the opinion of the physician, the benefit of treatment clearly outweighs the risks. For patients with sustained ventricular tachycardia, RYTHMOL® therapy should be initiated in the hospital. Initiation in hospital may also be required for certain other patients depending on their cardiac status and underlying cardiac disease. The effects of RYTHMOL® in patients with recent myocardial infarction have not been adequately studied and, therefore, its use in this condition cannot be recommended. There is no evidence from controlled clinical trials that the use of RYTHMOL® favourably affects survival or the incidence of sudden death. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to … https://pdf.hres.ca/dpd_pm/00062661.PDF PM date: August 26, 2021 Source product: RYTHMOL; DIN 00603708; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.